The HCC Virtual Experts Knowledge share will address “Appropriate selection of patients for 1^st line monotherapy in advanced or unresectable HCC and treatment management in relation with AEs”. The Faculty includes Dr Mohamed Bouattour (France) and Dr Su Pin Choo (Singapore) with presentations from Prof. Richard Finn, MD, (USA) and Dr. James Harding (USA)

The educational objectives for the meeting are:

• Explore the patient-profile who could benefit from VEGFR-TKI monotherapy 1^st line in advanced or unresectable HCC
• Interpret the real-world data and understand the implications for clinical practice
• Understand the safety profile of the monotherapies, be able to recognise the cause of toxicities and know the appropriate dosing strategies to manage side effects
• A look into the future, the potential of combination therapies in the treatment of HCC